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ABSTRACT

Antimicrobial Properties of Syringopeptin 25A and Rhamnolipids

by

Prerak T. Desai , Master of Science
Utah State University , 2005

Major Professor : Dr. Bart C. Weimer
Department: Nutrition and Food Sciences

The increasing bacterial resistance to available antibiotics requires the search for
new antibacterial compounds to be broadened. This study investigated the antimicrobial
properties of two secondary metabolites from fluorescent pseudo monads -- syringopeptin
25A, a lipodepsipeptide produced by Pseudomonas syringae pv . syringae , and a
rhamnolipid mixture produced by Pseudomonas aeruginosa. The rate of antimicrobial
action was determined by monitoring the rate of uptake of propidium iodide during
exposure to the compounds . Inhibition was also confirmed by the microbroth dilution
method to determine the MI Cs. Both the compounds inhibited growth of Gram-positive
organisms, including Mycobacterium smegmatis , staphylococci, and listeria. Inhibition
of spore germination was also notable. SP 25A inhibited two multiple antibiotic strains of

Staphylococcus aureus subsp. aureus and Enterococcus faecalis , while RLs failed to do
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so, even at 60 µg/ml. Addition of the compounds together showed a synergistic activity
against Listeria monocytogenes. Neither compound was toxic to human cells in vitro at 8
µg/ml.
It is postulated that both compounds exert their antimicrobial effect by forming
pores in the bacterial cell membrane, but we did not observe a relation between
membrane permeabilization and inhibition of growth in each case . At sub-MIC
concentrations RLs did cause pores in the membrane of L. monocytogenes , while SP 25A
did not. However , RLs did not inhibit cell growth , while SP 25A completely inhibited
cell growth .
To investigate these effects gene expression was monitored just before treating
the cells with the antimicrobials , 30 min after treatment and 120 min after treatment. The
gene expression profile was distinct when cells were treated with both the antimicrobials.
SP 25A repressed genes related to cell division, intermediary metabolism, transcription ,
translation, and virulence genes. These effects were not produced when cells were treated
with RLs, hence giving indications that even though both the antimicrobials may act on
the same site (i.e. the cell membrane), the cellular response was different, which led to
different phenotypes for growth.
This work indicates that SP 25A holds promise for further development as a
therapeutic agent and provides evidence that the proposed pore-forming model alone
does not suffice to explain the mode of action of SP 25A.
(105 pages)
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CHAPTER 1
INTRODUCTION

Very few developments in the history of health science have had such a profound
impact upon human life as the advances in controlling pathogenic microorganisms since
the discovery of penicillin. Though the application of antimicrobial agents preceded the
understanding of their action , it was not until the late 19th and early 20 th century that the
work of Pasteur and Koch firmly established that microorganisms as the cause of
infectious diseases and provided strategies that led to rational prevention and control
strategies . The first group of compounds discovered to suppress bacterial infections were
sulphonamides (2) . The success of sulphonamides along with the world wars stimulated a
massive hunt for more effective antimicrobials . Florey and Chain (3) succeeded in
isolating an impure but highly active preparation of penicillin and published their results
in 1940. The enormous success of penicillin quickly diverted a great deal of scientific
effort towards search of other antibiotics that culminated in the discovery or
approximately 3,000 named antibiotics. Of these, 50 have met with clinical use and many
fewer are regularly employed in therapy of infectious diseases (2).
The initial success of those antibiotics is now marred with emergence of resistant
organisms. Antibiotic resistance is a complex problem accelerated by the versatility of
the microbes, overuse of antibiotics, and the lack of patients completing the prescribed
dosage (1). Curable diseases such as gonorrhoeae and typhoid are becoming difficult to
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treat (4) due to resistance issues. However , the most troubling issue is the establishment
of vancomycin resistant organisms (4) . The solution to the problem of antimicrobial
resistance is very complex and a tough scientific issue. The primary path forward for
keeping infectious agents at bay is to continuously discover new antimicrobial
compounds. This path becomes easier if we better understand the mode of resistance and
susceptibility . With the advances in genomics, this task become should become easier
and faster. The knowledge obtained from system-wide genome analysis will help us in
designing better molecules to inhibit microbes in multiple modes.
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CHAPTER2
LITERATURE REVIEW

Molecular mechanisms of antibiotic action
The word antibiotic brings together a varied group of compounds with little in
common except for their antimicrobial activity. Hence , it is not surprising that they
prevent the growth of susceptible bacteria by different molecular mechanisms . The five
major mechanisms by which the antibiotics attack bacterial cells are (25 , 35, 40) :
1. Blockin g steps in cell wall synthesis. This group is exemplified by penicillin ,
cephalosporin, cycloserine , and vancomycin. These antibiotics interfere with the
biosynthesis of peptidoglycan and damage its cross linked macromolecular structur e
which can arrest growth and kill the bacteria.
2. Permeabilizing cell membrane. Polymyxin , tyrocidin , and va linomycin are examples
of this mode of action. When cells are treated with lethal doses of these antibiotics
they interact with the components of cell membrane , probably proteins , and induce a
lesion in the cell membrane hence impairing its ability to act as a semi permeable
barrier between the cell and its environment causing the cell components to leak out.
3. Inhibition of nucleic acid function. This group has examples including rifampicin ,
actinomycin D, and acridines . These compounds interfere at various stages
(nucleotide biosynthesis, polymerization of nucleotides) of DNA replication and
ultimatel y cause loss of gene expression , which is fatal to bacterial cells .
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4. Inhibition ofprotein synthesis. For example streptomycin, tetracyclines , and
chloramphenicol are used that act in this mode. These compounds bind the subunits
of ribosome and distort the ribosome enough to prevent normal codon anticodon
interaction leading to either inhibition of protein synthesis or faulty protein synthesis.
5. Inhibition of cellular metabolism. This is exemplified by sulphonamides. These
compounds inhibit the synthesis of folic acid by competing with p-amino benzoic
acid as a substrate for enzyme tetrahydropteroic acid synthetases that incorporates pamino benzoic acid into the folic acid molecule .

Antibiotic resistance in microorganisms
The development of microbial strains that are resistant to antibiotics is
unfortunately an ever increasingly common phenomenon . Antibiotic resistance may be
divided into two categories:
Intrinsic resistance: Generally Gram-negative bacteria are more resistant to
antibiotics than Gram-positive bacteria (4, 17, 35). This greater intrinsic resistance of
Gram-negative bacteria to antimicrobial agents may depend upon the nonspecific
permeability barrier presented by the outer membrane , preventing access of the antibiotic
molecules to their active site (4, 17, 35). Some bacteria may be inherently resistant due
to presence of various defense mechanisms like presence of antibiotic degrading
enzymes, presence of antibiotic efflux mechanisms or the organism may altogether lack
the drug target (4, 17, 35).
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Acquired resistance: Overuse of antibiotics and consequent antibiotic selective
pressure is thought to be the most important factor contributing to the organisms gaining
antibiotic resistance (4, 17, 25, 35, 39). Mechanisms by which the microbes gain
resistance may be due to spontaneo us mutations , transduction, transposons or conjugation
(25) . Bernard Davis (1952) first outlined the possible biochemical mechanisms of drug
resistance. They may be swnmarized as follows (4, 17, 35):
1. Conversion of an active drug to an inactive derivative (e.g. inactivation of P-lactam

antibiotics by P-lactamases) .
2. Enhancement of alternative metabolic pathwa ys (e.g. the pathways responsible for the
salvage of purin e and pyrimidine bases from nucleic acid catabolism) ; thereby
allowing their reutilization into new nucleic acids . This may be used to circumvent
the antibacterial activity of certain nucleic acid analogues.
3. Reduction in physiological importance of the target site, for e.g. bacteria may
overcome the antimicrobial action of sulphonamides by accumulating large amounts
of PABA (Para amino benzoic acid) .
4. Loss of cell permeability to a drug due to synthesis of an additional permeability
barrier (if the antibiotic gains access through passive transport) or due to loss of a
specific transport mechanism (i.e. if the antibiotic gains access through a particular
transport mechanism).
5. Modification of the antibiotic sensitive site (e.g. resistance to erythromycin in several
bacterial species depends on an alteration in a protein of the SOSribosome subunit
that leads to a reduced affinity of ribosomes for erythromycin).
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6. Active efflux of the antibiotic from the cytoplasm (e.g. resistance to tetracycline in
several Gram-positive as well as Gram-negative bacteria depends upon an ATP
dependent efflux system present in the cytoplasmic membrane).
Antibiotic resistance is a global health problem and is increasing . With every new
antimicrobial compound discovered or synthesized we are only a step ahead of microbes
before they become resistant. Recent increases in bacterial and fungal infections , the few
available antibiotics and the increasing resistance to the available antibiotics have
resulted in a broadening of the search for new inhibitory compounds .

Secondary metabolites from pseudomonads
as potential antimicrobials

Secondary metabolites from microbes are compounds produced and typically
secreted into the environment during the stationary phase of growth , and so are not
produced or required for growth (12, 30). The physiology of stationary phase cells is
adapted to restricted nutrients or another nutritional change, which allows the cell to shift
metabolism leading to the production of these compounds. One can think of this phase as
an environmental stress that result in changes in cellular metabolism that induces the
production of new compounds that are known as secondary metabolites. Often these
secondary metabolites are directed at inhibiting competing organisms that occupy the
same niche to give the producing organism a selective advantage . There are two ways to
increase ones competitive fitness in a 'tight' environment: self-improvement (increasing
ones own ability to gather nutrients) , or by decreasing the fitness of ones competitors.
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Siderophores and high-affinity nutrient uptake mechanisms are examples of how a cell
can increase its supply of nutrients (12, 30). Antibiotics and bacteriocins are examples of
how an organism can increase its supply of nutrients by crippling its competition (6, 12,
30).
Pseudomonads produce a variety of secondary metabolites that act as phytotoxins
or antimicrobial/antifungal

agents (6, 12, 30) (Table 2.1 ).Pseudomonads produce a wide

spectrum of chemically distinct and biologically active compounds that inhibit other
microbes. Among the most well characterized compounds are those produced by plant
pathogen Pseudomonas syringae and opportunistic pathogen Pseudomonas aeruginosa .
This study would be focusing on two compounds; syringopeptins produced by P.

syringae pv . syringae and rhamnolipids produced by P. aeruginosa owing to very
promising results obtained in the preliminary studies.

Syringopeptins
Syringopeptins (SPs) are a class of cyclic peptides substituted with fatty acids
known as cyclic lipodepsipeptides that are produced by several strains of P. syringae pv .

syringae. Currently , five different syringopeptins have been identified that vary in their
fatty acid chain length and number and composition of amino acids in the peptide moiety
(2, 3, 6, 13, 15, 16, 19, 23, 43). Syringopeptins contain either 22 or 25 amino acids
depending upon the specific bacterial strain from which it was purified. Often the Nterminal (2, 3-dehydro-2-aminobutyric

acid) is acylated with either 3-hydroxydecanoic or
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3-hydroxydodecanoic acid (5, 6, 24). An eight-member lactone ring is formed due to the
ester bond between allothreonine and C-terminal tyrosine (5, 6, 24). A high percentage of
hydrophobic amino acids are found in syringopeptins and it has been determined that the
peptide moiety is primarily composed of D-amino acids (5, 6, 24). The peptide sequence
of the syringopeptins may vary from strain to strain (5, 6, 24).
The conformation is characterized by three structural regions: 1) a loop including
the residues from Pro2 to Val6, 2) a helicoidal zone including the residues from Ala8 to
Alal 5, and 3) the lactone ring including Thrl 8 to Tyr25. This three-dimensional
conformation likely leads to changes in the membrane environment as discussed later in
this review (31) (Fig . 2.2) . Primarily , it is a phytotoxin and functions as a virulence factor
for P. syringae by playing a major role in inducing necrosis in plant cells (6). Studies
with knock out mutants have shown that organisms deficient in SP production are less
virulent, though some diseases may also occur in its absence ( 18). It has the ability to
cause electrolyte leakage by forming pores in plant plasma membranes , thereby
promoting transmembrane ion flux that leads to necrotic symptoms (23). It also displays
biosurfactant properties with a critica l micelle concentration of 0.9 mM for SP 25A and
0.4 mM for SP 22A, which may aid in the spread of organisms on the plant surface (6,

21).
Though the antimicrobial properties of this compound have yet to be fully
assessed, preliminary studies show promising results to inhibit many different bacteria.
Initial studies found these compounds inhibit Gram-positive bacteria at micromolar
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concentrati ons, with the MIC values ranging from about 1.5 to 37 µg/ml for variou s
organisms (Table 2.2) .
Little information about the mechanism is published describing the mode of
action of the SPs against bacteria , but the initial studies indicate that SPs form pores in
model membranes (3, 21, 23, 31, 43). It has been predicted that the SP molecule first
adsorbs onto the cell membrane with the hydrophobic acyl chain inserted between those
of the phospholipids of eel l membran e, while the hydrophobic linear peptide portion and
the hydrophilic cyclic moiety remain folded as they are in solution . Presumably , the
adsorbed monome rs form aggregates that eventually form the pore, since more than one
monomer is required to form a pore (14, 21) . After forming aggregate s the hydrophobic
portion unfolds and align s with the lipid tails spanning the membran e that causes the
formation of a pore. This pore formation is voltage dependent as observed in plan ar lipid
membranes (21) . Once the pore is formed , the cell would loose its permeability barrier
and ultimately lead to cell death .

Rhamnolipids
Rhamnolipids (RLs) are biosurfactants produced by several strains of

Pseudomonas aeruginosa (1, 7, 8, 12, 20, 30, 32, 33, 38). What makes these compounds
interesting is that it also shows antimicrobial activity the potential applications of which
could be enormous if they inhibit many types of bacteria (1, 7, 20) . RLs are often a
mixture of various homologues , depending upon the strain and carbon source provided
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during growth (33). Eleven different homologues have been identified in cultures of

P. aeruginosa (20) (Fig . 2.3). The physiological role of a specific RL is not well
understood , but since they have very good surface active properties they may:
1. Emulsify hydrocarbons or hydrophobic substrates making them available for cell
metabolism (28, 36).
2. Help the cells in swarming motility under nutrient limitations (28) .
3. Cripple the competing organisms for nutrients by the virtue of it antimicrobial
activity (1, 7, 20).
4. They may play a role as a virulence factor (34). In vivo RLs prevent phagocytosis of
the organism by macrophages by bringing about structural changes in the
macrophages so they cannot associate with the bacteria (34).
RLs have an array of applications due their versatility in bioactivity. A few of
them are as follows:
1. They are useful in bioremediation and biode gradation of organic compounds , both
aliphatic and aromatic. Addition of RLs to pure cultures of bacteria increase
biodegradation of hexadecane , octadecane, n-paraffin, phenanthrene, tetradecane ,
pristine and creosote (32) . This phenomenon could be due to their surface-active
properties since they increase the solubility of the hydrocarbons and hence make them
readily available to the degrading cells , or they may increase the surface
hydrophobicity of the cells by removing lipopolysaccharides from the cell wall
improving the association of more hydrophobic substrates with the cells (32).
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2. They have high affinity for a variety of toxic metals including cadmium , copper ,
lead , zinc, and lanthanum. This property makes them a potential flushing agent in
sites where bioremediation may be too slow or infeasible (32).
3. They are effective against zoosporic plant pathogens, such as Pythuim

aphonidermatum, Phytophthara capsici, and Plasmopara lactucae-radicis . In their
pure forms RLs render the zoospores nonmotile and bring about their lysis in Jess
than a minute at a concentration of 5-30 µg/ml (32) . Hence , they show potential for
biological control , too .
4. Due to their low toxicity ready biodegradability and excellent surface--active
properties they could be of great value in the cosmetic industry (42).
The antibacterial activity of RLs has not been fully explored nor exploited for
commercial value. These compounds are active against both Gram-positive as well
Gram-negative bacteria (1, 7, 20). The target for the action of rhamnolipids is the cell
envelope (1), presumably the physicochemical properties of the compound are
responsible for the permeabilization effect on the cell surface .

Use of high density oligonucleotide microarrays
to determine cellular response to inhibitors
The entire genome of several bacteria are fully sequenced , annotated , and
available in the public domain that can be used to assess the global impact of bacterial
inhibitors on gene expression. This along with the latest developments in high density
oligonucleotide microarrays represents a very powerful resource to understand the
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differential gene expression patterns in bacteria when subjected to different antimicrobial
compound treatments (22, 41, 44 ). By analyzing differential gene expression patterns of
bacteria when subjected to sub-MIC doses of antimicrobials , we have an opportunity to
uncover adaptive mechanisms employed by bacteria at the genomic level to overcome the
antimicrobial stress and also look at various secondary cellular responses. Stress
responses thus induced can be used to detect and characterize the mode of action of these
antimicrobials (9). In contrast to using single copy gene fusions (9) use of high density
oligonucleotide anays are better tools to understand the stress responses and when
combined to various pathway mapping tools like KEGG (26, 37) or Metac yc (27) , they
confer an opportunity to uncover the precise metabolic shifts leading to the expression of
a particular phenotype .
In context to the antimicrobials under investigation here , evidence is mounting
that for poreforming peptides, membrane permealization may not be the only mechanism
by which they inhibit bacteria (10). They may flocculate intracellular contents , alter
cytoplasmic membrane septum formation , inhibit cell wall synthesis, bind nucleic acids ,
inhibit protein synthesis or inhibit enzymatic activity (10). Also , it has been observed that
the antimicrobial activity may or may not correlate with the pore forming activity of the
peptide because evidence is available that bacteria can repair their cytoplasmic membrane
even when treated with lethal concentrations of the antimicrobial (45) giving conclusive
evidence that alternate mechanisms of cell death may be involved. Hence, in the light of
recent discoveries it becomes necessary to investigate the alternate mechanisms of the
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bactericidal effects of these compounds . Use of whole genome expression studies
currently seems to be the best alternative to achieve that.
In light of the need for new antibiotics and the broad indu stria l applications of SPs
and RLs, we have selected them for further study. We will use these compounds to
determine their potential to inhibit foodborne illness organisms as well as other pathogens
important to the agricultural sector.

Hypothesis
Syringopeptin 25A (SP 25A) and rhamnolipids (RLs) inhibit many species of
bacteria and their mode of inhibitions are distinct from each other.
The above hypothesis would be verified by realizing the following objectives.

Objectives
1. Screen candidate compounds for microbial inhibition and determine the minimum
inhibitory concentration for these compounds against selected bacteria
2. Based on results from the first objective, one organism will be used to determine
the cellular response to sub-MIC leve ls of SP 25A and RLs using gene expression
arrays.
Completion of these objectives will demonstrate the utility of a two new classes of
natural antibiotics to inhibit bacteria found in food and the environment.

Specific

commercial applications of these compounds may be possib le , but demonstration of those
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applications is beyond the scope of this initial project. Use of gene expression arrays will
offer insight into the mechanism of action and potential targets that are being inhibited by
the compounds in the cell. Most importantl y, this study will determine the differences in
the cellular response between two different classes of antibacterial compounds that are
produced by pseudomonads to inhibit other bacteria.
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Table 2.1 . Antimicrobial/antifungal secondary metabolites from pseudomonads.

Toxin

Pseudomonas species

Chemical Class

Pyo Compounds

P. aeruginosa

Quinoline derivatives

Pseudomonic
acid
Pyrrolnitrin

P. jluorescens

Organic acid

P. cepacia,
P. aureofaciens

Pyrrol derivatives

8, 10

Pyoluteorin

P. aeruginosa

Pyrrol derivatives

10

Azomycin

P. jluorescens

Pyrrol derivatives

10

Rhamnolipids

P aeruginosa

Glycolipids

Tabtoxin

P . .syringae

Monocyclic ~-lactam

Phaseolotoxin

P . .syringae

Sulfodiaminophosphinyl
peptide

Sperabillins

P. jluorescens

Substituted peptides

2-n-hexyl-5-npentyl resorcinol
& 5-n-heptyl
resorcinol

Pseudomonas spp .

Substituted resorcinols

8, 10

2,4 diacetyl
phloroglucinol

P. jluorescens

Substituted Phenols

8, 10

Obafluorin

P. jluorescens

~-Jactones

10

Tropolone

Pseudomonas spp .

Tropolone

10

7-hydroxy
tropolone
Thiotropocin

P. cepacia

Tropolone derivative

10

P. seudomonas spp .

Tropolone derivative

10

Phosphonomycin

P. syringae

Unknown

10

Syringomycin

P. syringae ,
P. fuscovaginae

Lipodepsinonapeptide

Reference

8, 10
8

8, 10, 11
8, 9
8, 9, 10
10

9, 10
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Pseudomycin

P. syringae ,
P. fuscovaginae

Lipodepsinonapeptide

9, 10

Syringotoxin

P. syringae ,
P. fuscovaginae

Lipodepsinonapeptide

9, 10

Syringostatin

P syringae ,
P. fitscovaginae

Lipodepsinonapeptide

9, 10

Syringopeptin

P syringae

Lipodepsipeptide

9,10

Tolaasin

P tolaasii

Lipodepsipeptide

9

Viscosin

P jluorescens

Lipodepsipeptide

9
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Table 2.2. Reported MIC values for SP 22A and SP 25A against selected organisms.

MIC (~M2

Reference

Organism
SP22A

SP 25A

Bacillus megaterium

1.56

3.12

(29)

Bacillus globigii spores

2.08

2.08

Weimer, unpublished data

Rhodococcus fascians

6.25

12.50

(29)

Micrococcus luteus

12.50

37.50

(29)

Listeria innocua

6.25

4.17

Weimer, unpublished data

Salmonella enteridis

6.25

8.33

Weimer, unpublished data

Mycobacterium smegmatis

1.63

NA

(11)
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Table 2.3. MIC values of rhamnolipids against selected organisms .

MIC
(µg /ml)
64
4

RL Mixture

References

RL47T2
RLLB1

(7, 20)

Enterobacter aerogenes CECT 689

4
>256

RLLB1
M7

( 1, 7)

Staphylococcus aureus ATCC 6538

8
128

RLLB1
M7

(1, 7)

Alternaria alternata

4

RLLB1

(7)

Proteus mirabilis CECT 170

8

RLLBI

(7)

Alcaligenes faecalis

32

M7

(1)

Serratia marcescens

16
8

M7
RL47T2

( 1, 20)

Klebsiella pn eumoniae CECT 17832

0.5

RL47T2

(20)

Clostridium perfringens

256
128

M7
RL47T2

(1, 20)

Escherichia coli

32
64

M7
RL47T2

(1 , 20)

Organism

Bacillus cereus var mycoide s A TCC 11778
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SP22
CH3(CH2)6~CH(OH)CH
...Dhb
2CCrOhb-Pro-Val-Val-Ala-Ala-Val-Val-Ohb-Ala-Val-Ala-Ala-Dhb--aThr-Ser-Ala

I

I

Tyr-Oab-Dab-Ala

SP25
CH3(CH2 )uCH(OH)CH
2CO-Dhb-Pro-Val-Ala-Ala-Val-Lcu-Ala-Ala-Ohb-Val-Ohb-Ala-Val-Ala-Ala-Dhb-aThr-Ser-Ala-Val

I

I

Tyr-Oab-Oab-Ala

Fig . 2.1. Structures of two syringopeptins with an amino acid backbone of 22 and 25
residues (6) . The fatty acids can either be 3-hydroxydecanoic or 3-hydroxydodecanoic
acid . Abbreviations for non-standard amino acids are: Dhb is 2, 3-dehydroaminobutyric
acid ; aThr is allothreonine.
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<
'

Fig . 2.2 Three-dimensional structure of SP 25A obtained by distance geometry
calculations from NMR analysis of the syringopeptin in D 20 at pH 3.6 (31).
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Fig. 2.3 . Generalized structure of a rhamnolipid. The carbon chain length may be n = 4, 6,
8 of C8, C 10, Ct2- In dirharnnolipids, R1 is Hor 3-hydroxydecanoate and R2 is L
rharnnosyl (1 ).
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CHAPTER 3
ANTIMICROBIAL SPECTRUM OF SP 25A AND RL'S AGAINST BACTERIA'

Abstract

Secondary metabolites from microorganisms are common sources of antibiotics.
However, recent increases in bacterial infections, the decreasing availability of potent
antibio tics and the increasing bacterial resistance to available antibiotics requires the
search for new antibacterial compounds to be broadened. In this study we investigated the
antimicrobial properties of two secondary metabolites from fluorescent pseudomonads syringopeptin 25A (SP 25A), a lipodepsipeptide produced by Pseudomonas syringae pv .
syringae , and a rhamnolipid mixture, which contained two primary types of glycolipids
produced by Pseudomonas aeruginosa. Human pathogens, food spoilage organisms, and
fermentative bacteria from both Gram-positive and Gram-negative classes were tested to
determine the inhibitory potential of these compounds. The rate of antimicrobial action
was determined by monitoring the rate of uptake of propidium iodide during exposure to
the compounds. Both compounds compromised the membrane of all the Gram-positive
bacteria with the rhamnolipids acting significantly faster (3-433 times depending upon
the organism tested) (p<0.05) than SP 25A. Inhibition was also confirmed by the
microbroth dilution method to determine the minimum inhibitory concentration (MIC) .
Both compounds inhibited all the Gram-positive organisms tested , as well as

1
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Flavobacterium devorans with MICs ranging from 3 µg/ml to 32 µg/ml. Both
compounds inhibited Mycobacterium smegmatis, Bacillus subtilis spores, and
Clostridium sporogenes spores with an MIC of 4 µg/ml. Interestingly, these compounds
acted synergistically to inhibit Listeria monocytogenes, thereby lowering the MIC for L.
monocytogenes. No toxicity was observed during exposure of these compounds to mouse
enteroendocrine, human embryonic kidney , and human lung fibroblasts. Taken together
these data support the conclusion that both of these compounds have potential for use as
antibacterial compounds which needs to be confirmed with in vivo studies.

Introduction
The ability to contro l infections due to microorganisms has been one of the single
most profound developments in the history of health science. The initial success of
antibiotics is now maned by the emergence ofresistant organisms (4). Antibiotic
resistance is a complex problem exacerbated owing to the versatility of the microbes,
overuse of antibiotics, and the lack of patients completing the prescribed dosage (4).
Among many issues of antibiotic resistance, one of the most troubling issue is the
establishment of vancomycin resistant organisms (36). The solution to this complex
problem remains to be identified, but discovery of new compounds is essential in solving
this issue.
One source of new antibiotics is the secondary metabolites of bacteria with
different modes of action. The antimicrobial potential of secondary metabolites of
fluorescent pseudomonads have been studied extensively (6, 11, 27). Among the most
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well characterized compounds are those produced by Pseudomonas syringae and
Pseudomonas aeruginosa . The ability of these organisms to inhibit competing

microorganisms via a myriad of mechanisms has inspired the search for new compounds
from these and other pseudomonads (6, 11, 27). Many pathovars of P. syringae produce
non-specific toxins (e.g. syringomycin, syringopeptin , coronatine , phaseolotoxin ,
syringotoxin, and tabtoxin) that increase the virulence of the organism to the host plant
(6) . Some of these toxins have antimicrobial and antifungal properties (6) which fuels
their use as biocontrol agents (22) . The most promising antibacterial activity is shown by
syringopeptins (SP) (6, 10, 26, 42) . In nature , SPs cause electrolyte leakage by forming
por es in the plasma membrane of plant cells, thereby promoting transmembrane ion flux
that leads to plant necrosi s (20). SPs also have biosurfactant properties with a low critical
micelle concentration (0.4-0 .9 mM) (12) that may aid in the spread of the organisms on
the plant surface (6, 19). Additionally SPs, along with syringomycin induce stomata!
closure in plants , thereby preventing entry of other pathogens , which effectively reduces
competition by other organisms on the plant surface (14) .
SPs are cyclic lipodepsipeptide s and are produced by many strains of P . .5yringa e
pv. syringae (2, 16, 38, 42) . Current ly, five different SPs have been identified. They vary
in the fatty acid chain length and number and composition of amino acids in the peptide
moiety (2, 5, 6, 16, 21) . SPs contain either 22 or 25 amino acids with the N-terminal
being acylated with either 3-hydroxydecanoic or 3-hydroxydodecanoic acid to 2, 3dehydro-2-aminobutyric acid (5, 6, 21). An eight-member lacton e ring is formed due to
the ester bond between allothreonine and C-terminal tyrosine (5, 6, 21 ). A high
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percentage of hydrophobic amino acids are found in SPs with the peptide being
composed ofD-amino acids primarily (5, 6, 21) ; however, the peptide sequence of the SP
varies from strain to strain (5, 6, 21) .
The mechanism of bacterial inhibition by SPs is unknown , however , initial studies
indicate that SPs form pores in the cell membrane (3, 19, 20, 28 , 40). It is hypothesized
that SP molecules adsorb onto the cell membrane via the hydrophobic acyl chain inserted
between the phospholipids in the membrane . Once the adsorbed monomers form
aggregates of sufficient concentration , a pore is formed (12, 19). However , this mode of
action remains to be proven , as does the minimum number of SP molecules required for
por e form ation .

P. aeruginosa is the epitome of opportunistic pathogens in humans, but the wide
interest in this organism not only stems from this but also from its wide catabolic
potential and the array of compounds with antibiotic activity that it produces (11 ). Cell
free culture supernatants from P aeruginosa were extensively used in therapy of
diphtheria, influenza and meningitis in the first quarter of the previous century, and since
it exhibited enzymatic properties it was called pyocyanase (27) . Subsequently , nearly 50
antimicrobial substances have been characterized from fluorescent pseudomonads ( 11).
This study focused on the antimicrobial properties of rhamnolipids (RL), which
are glycolipids produced by some strains of P. aeruginosa (7, 11, 29, 3 5). RLs are
usually a mixture of various homologues , depending upon the strain and carbon source
provided during growth (30). Eleven different RL homologues have been identified in
cultures of P. aeruginosa (17) and consist of one or two moieties of rhamnose cova lentl y
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linked to a 3-~ hydroxy acid, where the chain length of the acid is 8, 10, or 12 carbon
atoms. In some cases they may also have 3-hydroxy decanoate linked to the former fatty
acid via an ester bond. The physiological role of a specific RL is not well understood , but
they are thought to aid in emulsifying hydrophobic substrates for cellular metabolism (24,
34); aid the cells in swarming motility under nutrient limitations (24); cripple the
competing organisms for nutrients by the virtue of the surfactant activity (1, 7, 17); and
may act as a virulence factor (31 ). In vivo RLs prevent macrophage phagocytosis of the
organism by bringing about structural changes in the macrophages so they cannot
associate with the bacteria (31 ). The target for the action of RLs against other bacteria is
the cell membrane (1 ), presumably the surfactant properties of the compound are
responsible for the permeabilization effect on the cell surface. In this study we
hypothesized that SPs and RLs inhibit a wide spectrum of bacteria without causing
toxicity to mammalian cell lines. If true , these compounds may represent new options for
anti bacterial therapy.

Materials and Methods
Purification of antimicrobials. Syringopeptin 25A (SP 25A) was produced and
purified from Pseudomonas syringae pv . syringae Ml as described by Bidwai et al. (9).
In brief, the culture was grown to stationary phase for 10 d standing culture at room
temperature (-25°C). After collection of the supernatant SP 25A was extracted with
acidified acetone, concentrated with a rotary evaporator, purified to homogeneity by
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reverse phase HPLC, and lyophilized for storage at 4 ·c until further use . Purity and the
molecular weight of the compound were verified by MALDI-TOF analysis at the Center
for Integrated BioSystems (Logan, UT).
Commercial RL samples were obtained as 25 .1% aqueous solution (product JBR425 ; Lot#021004) from Jeneil Biotech , Inc. (Saukville , WI). The purity and molecular
weight of the RLs were determined using MALDI-TOF at the Center for Integrated
BioSystems . The relative concentrations via molar ratios between the two different
rhamnolipid moieties (Decanoic acid , 3-[(6-deoxy-L-mannopyranosyl)

oxy]-1-

(carboxymethy l) octyl ester , and Decanoic acid , 3-[(6-deoxy-2-0 (6-deoxy-Lmannopyranosyl)-L-mannopyranosyl]

oxy ]-1-( carboxymethyl)octyl ester) in the

commercial rhamnolipid mixture were determined by

13

C NMR as described by Sim et al.

(39) .

Determination of rate of antimicrobial action and the MICs against bacteria The
antimicrobial action for each compound was initially determined by the rate of uptake of
propidium iodide (PI) (Fluropure grade , Molecular Probes, Inc.; Eugene , OR) as
previously described (18). In brief, all cultures were grown overnight in their respective
optimal growth medium and temperature from freezer vials (Table 3 .1). Each culture
was sub-cultured twice, harvested in mid log phase , washed with saline and adjusted to
an OD 600 of 0.25 in saline. PI, with an excitation wavelength of 535 and an emission
wavelength of 617 , was added to the culture suspension at a final concentration of 10
µM. Each organism was treated with 50 µg/ml SP 25A and 60 µg/ml of the RL mixture
in a final volume of 2.2 ml. The increase in fluorescence was measured with a Shimadzu
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RF 1501 spectrophotoflurometer

(Columbia , MD) at 15 s interval s for a maximum period

of 120 min . Saline was added in place of SP 25A or RLs as a negative control . All
inhibition experiments were done in two biological replicates.
The rate of antimicrobial action was expressed as the inhibition rate (IR) (Eq. 1).
The curve fitting was done using OriginPro Ver 7.0 (Natick , MA).
IR = ((Log RFU / (Time)) - C) / Time (when d Log RFU / dT > 0)

(Eq. 1)

Where RFU = relative fluorescent units ; and C = Y intercept
The minimum inhibitory concentration (MIC) for the organisms were determined
by microbroth dilution method as prescribed by the National Committee for Clinical
Laboratory Standards (NCCLS) (44). The microorganisms were prepared as described
above and resuspended in their optimal growth media (Table 3 .1) to - 105 CFU/ml
containing SP 25A at 2, 3, 4, 5, 6, 7, 8, 16, 32 and 50 µg /ml in a total volume of 550 µI.
RL concentrations of 2, 3, 4, 5, 6, 7, 8, 16, 32 and 60 µg/ml in a total volume of 550 µl
were tested in a 48-well plate (Corning , NY) , unless otherwise noted. The plates were
incubated in optimal growth conditions for the respective organism and monitored for an
increase in OD 6oo after 48 h by a Perkin-Elmer (HTS 7000) plate reader (Downers Grove ,
IL) . A positive control (inhibition of growth) using Polymyxin B (Sigma-Aldrich Cat#
P0972) at 1000 µg /ml for all Gram-negative organisms, Penicillin G (Sigma-Aldrich
Cat# P3032) at 1000 µg/ml for the Gram-positive organisms, Rifampicin (Sigma-Aldrich
Cat# 3501) at 1000 µg/ml was used for M smegmatis, Enterococcusfaecalis

and

Staphylococcu s aureus . Negative controls (no inhibition of growth) were included using
saline in the assay for each compound. The least concentration at which there was no
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increase in OD over 48 h was reported as the MIC. Each MIC was determined in two
biological replicates with triplicate tests per replication. The triplicates were averaged for
each replicate reported.
Synergistic activity between SP 25A and RLs was measured by exposing L.
monocytogenes to RLs at a concentration of 0, 0.5, 1, 1.5, 3, and 6 µg/ml alone and in

combination with 3 µg/ml SP 25A and monitoring PI uptake as previously described . The
expe riment was done in two biological replicates .
Determination of cytotoxicity in cell culture. Toxicity of the two compounds to

mammalian cells was assayed in cell culture using mouse enteroendocrine cells (STC-1)
(37), human embryonic kidney cells (HEK 293; ATCC CRL-1573), and human lung
fibroblasts (LL47 ; ATCC CCL-135) . Each cell line was subjected to SP 25A and RLs at
the observed MIC (e.g. 4 µg/ml and 8 µg/ml) . The human embryonic kidney cells and
hurnan lung fibroblasts were grown as per the ATCC recommendation, while the mouse
enteroendocrine cells were grown as described by Vincent et al. (37). Media and sera
were purchased from HyClone Laboratories (Logan, UT). All cells were grown in 10%
fetal bovine serum (FBS).
The number of total cells and dead cells were counted after 6, 24, and 48 h using
a Nucleocounter Automated cell counting system (New Brunswick ; Edison , NJ). In brief ,
cells (STC - 200,000 cells/well , HEK 293 - 200,000 cells/well and LL47 - 100,000
cells/well) were incubated with the appropriate medium for 24 h prior to addition of fresh
media containing the antimicrobial compounds . After addition of the antimicrobial
compound the cell cultures were incubated at 37°C with 5% CO 2 for 6, 24, and 48 h.
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Cells were harvested by trypsinization using 0.25% trypsin-EDT A for 2 min . The trypsin
was neutralized by addition of 200 µl of serum containing fresh medium . The cells were
harvested and transferred to 1.5 ml tubes , centrifuged (3-5 min at < l 00 x g), and
resuspended in 200 µl of fresh medium. Subsequently , for total cell count 100 µl of the
cell suspension was added to the Ly sis buffer (Reagent Al 00 in the starting kit (Cat No.
Ml293-0020, New Brunswick Scientific) for 30 s, which was stabilized using 100 µl of
Reagent B. A positive control of completely lysed cells by lysing all the cells with triton
was used along with a negative control using sterile PBS (pH 7.4) . For dead cell counts
100 µl of cell lysate was counted without use of lysis buffer or stabili zing buffer. All cell
counts were obtained using the Nucleocounter automated cell counting system . Data were
reported as the percent of cell death. The toxicity testing was done in two biological
replicates with triplicate wells per replication . The triplicates wells per replication were
averaged before reporting the replicate reading.

Results and Discsussion

Compound purity. After purification SP 25A was subjected to MALDI-TOF and
HPLC analysis to confirm the purity of the fractionated compound. HPLC analysis
revea led a single peak , as did MALDI TOF (Appendix A, Fig A l ). This single major
peak had a molecular weight of 2,400.37 Da, which was in agreement with the reported
size (33).

36
The commercial RL preparation was subjected to MALDI-TOF analysis and

13

C

NMR to determine the relative concentration and isoform content, respectively. MS
analysis revealed Rhamnose-C 10-C 10 (MW = 503 .31) and Rhamnose-Rhamnose-C 10C10 (MW= 649.33) (Appendix A, Fig A2). These observations are in agreement with the
product data sheet. NMR analysis demonstrated that the isoforms were present in an
equimolar ratio.

Bacterial inhibition by SP and RLs. It is thought that these compounds target the
cell membrane, inducing lysis (6, 12, 25) . This study used PI, a membrane impermeant
nucleic acid stain , as a probe to monitor cell membrane integrity during cellular exposure
to both compound types (18). PI accumulation directly correlated to increasing exposure
time for each compound , indicating that the compounds compromised the cell membrane.
As such , the rate of PI accumulation (Eq . 1) was used to compare the inhibitory rate for
each organism tested (Fig. 3 .1).
SP 25A was not inhibitory to any of Gram-negative organisms tested except F.

devorans , while it inhibited all Gram-positiv e organisms tested . Also , SP 25A did not
inhibit the growth of any yeast tested (Breltonomyc es bruxellensis, Candida vini, Pichia

ferment ans, Saccharomyces luduigi, Metschinikowia pulcherrima , Kloeckera apiculata)
(data not shown). The greatest rate of inhibition was found for Brevibacterium linens,
while E. faecalis had the slowest rate of inhibition (Fig. 3 .1).
As observed with SP, RLs inhibited only Gram-pos itive bacteria (except F.

devorans) , with activity being the fastest against B. subtilis (Fig. 3.1) and slowest against
both the two Listeria species tested . The rate of action was distributed differently relative
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to SP 25A , but the same Gram-reacting organisms had the same inhibition for each
compound .
There was a significant difference (p<0.01) in the rate of PI accumulation (IR)
between SP 25A and RLs. Depending upon the species RLs were 3 to 433 times faster in
the compromising the cell membrane as compared to SP 25A, the difference being
highest for enterococci and lowest being for the Listeria species
While the rate of action indicates the speed to compromise the membrane, an
indication of the MIC is required to demonstrate inhibition of growth. Therefore , the MIC
for each compound was determined (Table 3.2). Measuring inhibition with MICs
confirmed the observations using PI.
The SP 25A MIC ranged from 3 to 16~tg/ml, while the MICs for RL ranged from
4 to 32µg /ml for the organisms tested. Interestingly , a difference in the SP 25A and RL
MIC with E.fa ecal is and S. aureus was observed (Table 3.2). While the MIC for RLs for
both these organisms was >60 µg /ml , SP 25A completely inhibited both the organisms at
8 µg /ml. For all the other organisms SP 25A had a similar or lower MIC as compared to
RLs . Interestingly , both compounds inhibited spore germination from Bacillus and

Clostridium at 4µg /ml. This work is the first report of anti-spore activity by these
compounds. Both the organisms inhibited growth of M smegmatis at 4µg /ml.
Lavermicocca et al. (26) measured the antibacterial activity of SP 25A using six
organisms. No inhibition was observed for the three Gram-negative organisms, even at
120 µg /ml. However , all three Gram-positive bacteria were inhibited (Micrococcus

luteus, Bacillus megaterium , and Rhodococcus facians). While the overall observations
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are in agreement between this study and Lavermicocca et al. (26), the exact
concentrations are not comparable, unfortunately, due to differences in methodology.
Antimycobacterial activity was found by Buber et al. (10), but due to the method
of isolation they were unable to conclusively assign this activity to SP 25A. In this study
we conclusively found that SP 25A inhibited M smegmatis, a surrogate organism for

Mycobacterium tuberculosis, at 4 µg/ml.
The literature contains conflicting reports on the spectrum of activity for RLs.
This may be attributed to the fact that different groups have used RL mixtures with
different compositions of RL homologues . For example , Abalos et al. (1) , Benincasa et
al. (7), and Haba et al. (17) reported that RL mixtures are active against both Grampositive and Gram-negative bacteria . In this study , we found RLs that were active against
Gram-positive bacteria and only one Gram-negative bacterium (F. devorans) at <60
µg/ml. Kim et al. (8) reported the ability of RLs to lyse zoospores from Phytophthora

capsici within 1 min at a concentrations <50 µg/ml. Conversely , we observed that RLs
inhibited bacterial spore germination in B. subtilis and C. sporogenes at 4 µg/ml.

Synergistic activity. Since both compounds demonstrated a similar range of
activity and MICs , we determined the synergistic activity in an effort to reduce the MIC
for each compound. This was done by exposing L. monocytogens to mixtures of SP 25A
at 3 µg/ml with various RLs concentrations. The IR for the mixture of both the
compounds was significantly different (p<0.05) than the IR of the compounds used alone
across all concentrations tested , hence satisfying the classic definition of synergism. We
achieved a higher rate of antimicrobial action when both the compounds were used in
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combination as compared to individual use. Using the compounds together we were able
to achieve the sam e level of inhibition with up to 6-fold less RLs. The increase in
synergism followed a sigmoidal curve (Fig 3.2) .
This is the first study to define the synergistic activity of SP 25A and RLs . Woo et
al. (43) reported synergistic activity of SPs with fungal cell wall degrading enzymes to
inhibit fungal pathogens . Also , there have been reports of synergism between cationic
pore forming peptide s (23) , but there has been no report of synergism between a
lipodepsipeptide and a glycolipid . The importance of this finding is best refined for use
in specific applications , and is therefore beyond the scope of this work.

Cellular toxicity . Three mammalian cell lines were used to assess cytotoxic
effects for each compound at 4µg/ml and 8µg /ml. No significant (p>0.05) cytotoxicity
was observed at 6, 24, and 48 h after treatment for each compound at either
concentrations (Fig . 3.3). While a small amount of lysis was observed, it was not above
background . Cells treated with triton (positive control) showed 100% lysis. These
observations indicate that neither compound compromised the host membrane. Various
groups (13 , 15, 41) reported haemolytic activity of SP 25A. Menestrina et al. (15)
reported a Cso value of 8.88 µg/ml of SP 25A for RBC hemolysis. In contrast , at similar
concentrations, we did not observe membrane permeabilization of any of the three cell
lines tested. A possible explanation of this observation is that RBC's lack an
endomembrane, which is thought to play a central role in the rapid resealing response in
event of plasma membrane disruption (32) .
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Although structurally different both the compounds have a similar spectrum of
activity for the strains tested . One aim of this study was to determine the use of these
compounds against multiple drug resistant strains. This was done using E. faecalis and S.

aureus that are gentamicin/vancomycin/teicoplanin resistant and MRSANISA ,
respectively. We observed that RLs had a higher IR than SP 25A, yet RLs were unable
to inhibit growth at 60 µg/ml. This is similar to the concept described by Wu et al. (45) ,
who found that cationic peptides were not correlated with the ability to permeabilize the
cell membrane and the antimicrobial activity.
Several inferences can be made from this lack of correlation . The biochemical
changes brought about by RLs were overcome by a stress response that repaired the
compromised membrane , but they could not repair the changes brought about by SP 25A.
This reveals that either the compounds have a differing mode of action on the cell
membrane or SP 25A has multiple modes of action (i.e. it may act on multiple cellular
targets) . Membrane repair in response to cationic peptides was reported by Wu et al.
(45). They observed that some peptides did not depolarize the cell membrane at MIC
concentrations , suggesting that at these MICs bacteria repaired their cell membrane and
that a mechanism other than membrane disruption leads to cell death. In this study , we
observed RLs to disrupt the membrane enough to up take Pl, yet the organisms retained
the ability to replicate.
This study demonstrated the ability of SP 25A and RLs to compromise the
membrane of Gram-positive bacteria with MI Cs of S8 µg/mJ. The compounds acted
synergistically to inhibit L. monocytogenes resulting in lower MICs for each compound
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when used in combination . Considering the inhibition of multiple drug resistant
enterococci and staphylococci , Mycobact erium, Bacillus spores , and the lack of toxicity
towards mammalian cells makes SP 25A a very promising therapeutic agent , which needs
to be confirmed with in vivo studies .
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Table 3 .1. List of bacteria used for antimicrobial scree nin g and their growt h conditions .

Organism

Strain

Temperature
(°C)

Oxygen
Demand

Aeromo nas caviae

13137

30

Aerobic

Bacillus cereus

10987

30

Aerobic

Bacillus subtilis

23857

26

Aerobic

Bacillus megaterium

14581
BLl
MGE

30

Aerobic

Nutrient
agar
Nutrient
agar
Nutrient
agar
NB

37

Aerobic

TSB

Brevibacterium linens

Medium

Nutrient
agar
Reinforced
clostridial
medium
Nutrient
agar

Citrobacter fruendii

11811

37

Aerobic

Clostridium sporogenes

10000

37

Anaerobic

Enterobacter aerogenes

13048

30

Aerobic

Enterococcus fa ecal is

700802

37

Aerobic

Erwinia herbicola

33243

37

Aerobic

Eschereschia coli

K12

37

Aerobic

Eschereschia coli H7:0l 57

35150

37

Aerobic

Flavobacterium devorans

10829

30

Aerobic

Klebsiella pneumoniae sub sp
pneumoniae

700721

37

Aerobic

NB

Lactobacillus plantarum

8014

37

Microaerophilic

MRS

Lactobacillus acidophilus

4355

37

Microaerophilic

MRS

Lactococcus lactis subsp lactis

IL1403

30

Microaerophilic

Listeria innocua
Listeria monocytogenes
Micrococcus luteus
Mycobacterium smegmatis
Saimonella typhimurium

33090
43251
21102
14468
13076

37
37
30
37
37

Aerobic
Aerobic
Aerobic
Aerobic
Aerobic

BHI
Nutrient
agar
Nutrient
agar
Nutrient
agar
Nutrient
agar

Ellikers
Broth
BHI
BHI
BHI
Luria Broth
Nutrient
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Salmone lla enteridis
Staphylococcus aureus subsp
aures
Streptococcus mutans
Streptococcus suis
Streptococcus agalacticae
Bacillus subtilis (spores)
Clostridium sporogenes(spores)

700931

37

Aerobic

agar
TSB

700699

37

Aerobic

BHI

89/1591
700610
12403
6633

37
37
37
26

Aerobic
Aerobic
Aerobic
Aerobic

BHI
BHI
BHI
TSB

Anaerobic

Reinforced
clostridial
medium

11437

37
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Table 3.2. MICs (Two biological replicates done in duplicate) and mean IR's (2
biological replicates) of SP 25A and Rhamnolipid mixture against screened organisms.
(ND represents Not Determined).

Genus

IR
Rhamnolipids
(60µg /ml)

Bacillus megaterium
Listeria innocua
Listeria monocytogenes
Bacillus cereus
Bacillus subtilis
Clostridium sporogenes
Flavobacterium devorans
Lactococcus lactis subsp. Lactis
Micrococcus luteus
Mycobacterium smegmatis
Streptococcus mutans
Streptococcus suis
Bacillus subtilis (spores)

1.043
0.014
0.032
0.834
1.807
0.698
0.518
1.219
0.183
ND
0.164
1.018
ND

Clostridium sporogenes(spores)
Enterococcus faecalis
Lactobacillus acidophilus
Staphy lococcus aureus subsp. aureus
Streptococcus agalacticae
Lactobacillus plan/arum
Aeromonas caviae
Citrobacter fruendii
Enterobacter aerogenes
Erwinia herbicola
Eschereschia coli Kl 2
Klebsiella
pneumoniae
Pneumoniae
Salmon ella typhimurium
Salmonella enteridis
Brevibacterium linens
Eschereschia coli H7: 015 7

MIC(µg /ml)

IR SP
25A
(50µg /ml)

MIC(µg /ml)
,..,

5
6
4
4
4
16
4
8
4
4
4
4

0.005
0.005
0.005
0.004
0.006
0.008
0.002
0.008
0.006
ND
0.003
0.006
ND

4
4
4
4
4
4
4
4
4
4

ND
0.482
0.196
0.894
1.073
0.287
0.000
0.000
0.000
0.000
0.000

4
>60
16
>60
4
32
>60
>60
>6 0
>60
>60

ND
0.001
0.003
0.003
0.004
0.003
0.000
0.000
0.000
0.000
0.000

4
8
8
8
8
16
>50
>50
>50
>50
>5 0

0.000
0.000
0.000
0.512
0.000

>60
>60
>60
ND
ND

0.000
0.000
0.000
0.009
0.000

>50
>50
>50
ND
ND

4
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error bar s repre sent SEM from two biolog ical replicat es.
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CHAPTER4
GENE EXPRESSION PROFILE OF LISTERIA MONOCYTOGENES EGDE IN
RESPONSE TO SUB-MIC DOSES OF SYRINGOPEPTIN 25A AND
RHAMNOLIPIDS

Abstract
Two antimicrobial compounds that target the cell membrane , syringopeptin 25A
and an equimolar mixture of two rhamnolipids , were used to determine the cellular
response during sub-MIC treatment with Listeria monocytogenes EGDe. Cell growth,
membrane permeabilization and the gene expression profile was determined immediately
prior to treating the cells with either antimicrobial , after 30 min of exposure , and after
120 min of exposure . Cell membrane permeabilization was highest after treating the cells
with rhamnolipids , which also resulted in a 4 7 % reduction in growth. However, growth
inhibition was 100% after treatment with SP 25A , despite having only - 2% increase in
dye uptake . Treatment of L. monocytogenes with SP 25A significantly changed the
expression of 139 genes , while treatment with rhamnolipids resulted in significantly
different expression of 3 9 genes. SP 25A repressed 97% of the differentially regulated
genes, while RLs induced 70% of the differentially regulated genes after 120 min of
treatment. The effective reduction in cell density after treatment with SP 25A was
associated with the repression of key genes involved in cell division and genome
replication; hence , inhibiting cell division. SP 25A also repressed key genes in central
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metabolism , generation of precursor metabolites , transcription, and translation resulting
in repression of RNA production , protein biosynthesis, cellular energy , and virulence.
Rhamnolipids , conversely , affected only a few genes within any single functional
category that were not associated with any single phenotypic observation . Hence , SP 25A
caused repression in the cell's metabolism , which was independent of the observed pore
forming activity. Taken together these data led us to conclude that both the compounds ,
even-though acting on the cell membrane , produced distinctly different gene expression
profiles with SP 25A being more effective to inhibit cell growth in L. mono cytoge nes.

Introduction
The increase in multiple antibiotic resistant strains , which leads to more
nosocomial infections and community-acquired infections , has fueled the search for new
antibacterial compound s, including peptides. Antimicrobial peptides are pervasive
components of prokaryotic and eukaryotic defense mechanisms against invading
organisms (9). Though structurally diverse , the amphipathicity and cationic nature of
these peptides allows them to interact and disrupt the bacterial cell membrane leading to
cell death (3 5). Subsequent effects on intracellular molecules have also been observed ,
leaving some investigators to conclude that membrane disruption is only a portion of the
antimicrobial activity (16, 36).
The mode of action to disrupt the membrane with peptide antibiotics is thought to
follow the "barrel stave" model that form pores across the membrane or the "carpet"
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model, where the molecules align orient parallel to the membrane and disrupt the lipid
structure (28) . While it seems alluring to endow the antibacterial effect of these
compounds solel y to thes e two models , these mechani sms alone do not account for the
physiological effects that these peptide s produce in bacterial culture s (8). Wu et al. (35 )
and Friedrich et al. (16) observed that some cationic peptides failed to depolarize the
bacterial membrane , yet effectively inhibited growth. At the MIC concentration these
peptides did not disrupt the bacterial membrane , giving conclusive evidence that a
general membran e disruption mechanism alone cannot account for antimicrobial
properties of all peptide s (15 , 35). Furth er, Tomasin sig et al. (32) and Hon g et al. (17 )
found that cationic peptides resulted in changes in gene expression profiles in E. coli in
addition to perrneabilizing the membrane.

Taken together , these data provide evidence

that it is unlikely that the diverse groups of peptides act via only membrane disruption
alone . Once inside the cytoplasm these peptides may bind proteins , DNA , RNA , or other
macromolecules to alt er replication and m etabolism (8) .
Cyclic lipopeptides are potent antimicrobial and two compounds of this class
polymyxin B (14) and daptomycin (26) are approved by the Food and Drug
Administration for clinical use . Syringopeptin 25A (SP 25A), a cyclic lipodepsipeptide
produced by Pseudomonas syringae pv. syringae is structurally similar to daptomycin. SP
25A consists of 25 amino acid residues with the N-terminal being acylated with 3hydroxydecanoic acid. An eight -member lactone ring is formed via an ester bond
between allothreonine and C-terminal tyrosine (3, 5, 19). Hydrophobic amino acids
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account for 68% in syringopeptins with the peptide being composed of primarily Damino acids (3, 5, 19).
In a previous study , rhamnolipids (RLs) showed a similar spectrum of activity to
inhibit bacteria , as compared to SP 25A ( 13). RLs are surfactants with 11 homologues
produced by some strains Pseudomonas aeruginosa and consist of one or two moieties of
rhamnose covalently linked to a 3-~ hydroxy acid, where the chain length of the acid is 8,
10, or 12 carbon atoms (6). In some cases they may also have 3-hydroxy decanoate
linked to the fatty acid moiety via an ester bond. RLs are usually a mixture of various
homologues , depending upon the strain and carbon source provided during growth (23) .
In a previous study Desai and Weimer (13) found no correlation between the bactericidal
activity and membrane permeabilization of SPs and RLs. In a multi drug resistant strain of
Staphylococcus aureus, RLs induced higher propidium iodide (PI) uptake , indicating an
increase in membrane penneabilization , as compared to SP 25A , but RLs did not inhibit
the cell growth. This confirms the observations of others for the disconnection of
membrane disruption and growth inhibition (8, 13, 15, 16, 18, 33, 35).
A number of groups have used transcription profiling during challenges with subMIC doses of antimicrobial compounds to find that some antimicrobial peptides invoke
cellular changes that are not lytic and not lethal (1, 10, 17, 32, 34 ). These experiments are
leading to the discovery of the multiple targets for antimicrobial peptides beyond the
membrane . Such observations imply that the peptides directly or indirectly interact with
membrane proteins leading to regulatory components, which affects the susceptibility of
the organism to the compound, which has been observed in Salmonella enterca and P.
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aeruginosa (32). In this study, we hypothesized that sub-MIC doses of SP 25A or RLs
will evoke distinct gene expression responses that will provide genetic targets that are
additional mechanisms of action to inhibit bacterial growth that are not membrane
associated.

Materials and Methods
Purification of antimicrobials . P. syringae pv. syringae Ml was obtained from the
Utah State University culture collection. SP 25A was produced and purified as described
by Bidwai et al. (7). In brief, the culture was grown to stationary phase for 10 d standing
culture at room temperature (- 25°C). After collecting the supernatant , SP 25A was
extracted with acidified acetone, concentrated with a rotary evaporator , purified to
homogeneity by reverse phase HPLC , and lyophilized for storage at 4 °C for further use .
The purity and molecular weight were verified by MALDI -TOF analysis at the Center for
Integrated BioSystems (Utah State University , Logan, UT).
Commercial RL samples were obtained as a 25 .1% aqueous solution (product
JBR-425; Lot#021004) from Jeneil Biotech, Inc. (Saukville , WI). The purity and
molecular weight of the RLs were determined using MALDI-TOF at the Center for
Integrated BioSystems. The relative concentrations via molar ratios between the two
different rhamnolipid moieties (Decanoic acid , 3-[(6-deoxy-L-maimopyranosyl)
(carboxymethyl) octyl ester, and Decanoic acid, 3-[(6-deoxy-2-0 (6-deoxy-Lmannopyranosy l )-L-mannopyranosy l] oxy ]-1-( carboxymethyl )octy 1 ester) in the

oxy ]-1-
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commercial rhamnolipid mixture were determined by

13

C NMR as described by Sim et al.

(29) .

Bacterial strain, growth conditions and gene expression profiling. Listeria
monocytogenes EGDe was thawed and subcultured twice at 37°C in brain heart infusion
broth (BHI) (DIFCO , Franklin Lanes, NJ). An overnight culture was diluted 10 fold in
sterile medium and grown for 4 h to an OD 600of 1.7, which corresponded to ·- 109 cfu/ml.
The cell preparation was exposed to either 3µg /ml SP 25A or 6 µg /ml RLs. Previously,
Desai and Weimer (13) determined the MIC for L. monocytogenes with SP 25A to be 3
µg /ml and 6 µg /ml with RLs . This study used these concentrations , but increased the cell
population to - 109 cfu/ml, rather than 105 cfu/ml , the cell density used to determine the
MIC. Thereby, making SP 25A and RLs sub-MIC at 3 µg/ml and 6 µg /ml , respectively .
Total RNA was extracted from 1.8 ml culture immediately before treating the
cells with SP 25A and RLs (To), after 30 min (T30), and at 120 min (T120)of exposure at
37°C. Simultaneously, the cell density was measured at OD 600. Membrane
permeabilization was determined by measuring the PI uptake as described by Desai and
Weimer (13). Total RNA extraction and reverse transcription (from 10 µg total RNA)
was done as described by Yi et al. (36) to produce biotinylated cDNA, which was sheared
with DNasel as described by the protocol ofNimbleGen

Systems (Madison, WI). The

custom, optimized NimbleScreen chip contained 12 wells, enabling the entire experiment
to be done on a single chip. Each well contained five probes for each open reading frame
in the entire genome.
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Hybridization of the fluorescently-labeled (Cy3 -st reptavidin ; Amers ham
Biosciences , Piscataway , NJ) cDNA (500 ng) was done using a custom NimbleScreen
chip optimized for L. monocytogenes EGDe, as described by the NimbleGen Systems
protocol. Hybridization was detected with a Genepix 4200A array scanner (Axon
Instruments , Union City, CA) at the Center for Integrated BioSystems. Data extraction
from the scanned images was completed at NimbleGen Systems . The raw expression data
from the entire experiment were normalized together using R with the robust multichip
average (RMA) method ( 18). Appendix C lists the R code used for RMA normalization .
Annotations for Listeria monocytogens EGDe were obtained from the ERGO database
(Integrated Genomics , Chicago, IL) .

Statistical analysis and data visualization. RMA normalized data were analyzed
using SAM Version 2.01 (33) with a one class time course experimental design using the
xCluster R module (Center for Integrated BioSystems). Any gene with at least a log 2 ratio
of ±0.58, which is equivalent to a 1.5 fold change, and a Q<0.3 was considered
significant (30). The entire biological experiment was replicated twice.
Heat maps were drawn with log 2 values of the RMA normalized data after
calculating the average of the biological replicates using Hierarchicai Clustering Explorer
version 3.0 (27). The log2 ratios were calculated by taking a difference in log 2 intensity of
a single time point with the preceding time point.
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Results
Compound purity and growth inhibition. The commercial RL preparation was
tested using MS and

13

C NMR to determine the isoform content and relative

concentration , respectively.

13

C NMR analysis revealed Rhamnose-C 10-C 10 (MW=

503.31) and Rhamnose-Rhamnose-ClO-ClO

(MW= 649 .33) to be present in an

equimolar ratio . These observations are in agreement with the product data sheet.
The compound purity was tested to ensure the compound identity before use in
the study of growth inhibition . SP 25A isolated in this study was a single compound
(Appendix A, Fig Al) , but the commercial RL preparation was a mixture of two isoforms
(Appendix A, Fig A2). The pure SP 25A had a molecular weight of 2,400 .37 Da, which
was in agreement with the reported molecular weight for SP 25A (24) .
Both antibacterial treatments caused membrane permeabilization (Fig . 4.1A) , but
reduced cell growth (Fig. 4.18) of L. monocy togenes by different amounts . Addition of
RLs resulted in more membrane permeabilization than did the addition of SP 25A. After
30 min of incubation with RLs the permeabilization increased by 53% ; while
permeabilization due to SP 25A increased 2.6% during the same time . Interestingly , the
permeabilization declined after 120 min of treatment with RLs.
The cell densit y was highest in the control , as expected , and lowest with addition
of SP 25A. The control culture increased growth by 15.3% during 120 min , while the
culture treated with RLs increased by 8%, but those treated with SP 25A did not increase.
The membrane permeabilization and the cell density changes did not correlate (Fig. 4.1 ),
suggesting that the mechanism of action for both compounds was not just membrane
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permeabilization.

To determine the underlying mechanisms responsible for these

differences, gene expression profiles were determined.

Gene expression profiling with RLs. The expression data were examined for genes
that were constitutively expressed above the mean expression level , but none were found ,
indicating that gene expression changed over the exposure time. At T 30RLs induced eight
genes and repressed two genes. Treating the cells for 120 min with RLs significantly
altered the expression of 39 genes. Regulation of 21 common genes was observed
between SP 25A and RLs (Table 4.1 ). Despite regulating these common genes , the
patterns of expression between the two classes of the antimicrobial compounds were
different. At T 120, 27 genes were induced and eight were repressed.

Intermediary metabolism and oxidative phosphorylation. RLs induced three
PEP/PTS components, a-mannosidase (LM00401), and five other genes involved in
glycolysis and pentose phosphate pathway (Table 4.2). Conversely , all these genes were
repressed when cells were treated with SP 25A during the same time period. The H+transporting ATP synthase C (atpE) was induced at T 30, but subsequently repressed at
T 120.Fig D 1 and D2 from Appendix D gives the heatmaps of genes affected in these
functional category

Protein biosynthesis and virulence factors. No genes related to transcription were
differentially regulated after treatment with RLs. Only one gene related to protein
biosynthesis, phenylalanyl-tRNA synthetase alpha chain (pheS (LM01221)) was induced
at T30. An acetyltransferase (LM00624) involved in post translation modification was
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repressed at T 3 o, but induced at T120(Table 4.2). Fig D3 and D4 from appendix D gives
the heatmaps of genes affected in these functional category
Of the four virulence factors in the genome , only listeriolysin O (hly) was induced
after 120 min of treatment. Expression of the remaining virulence factors was not
change d by addition of RLs.
Stress genes. Four stress -related genes -- single strand bindin g protein (ssb), nonheme iron binding ferritin (fri), and heat shock protein cspL, and peroxide operon
regulator p erR (LM01683) -- were induced after 120 min . However , none of the genes in
the perR regulon were induc ed. No other genes were significantly regulated durin g
treatm ent with RL s.
Gene express ion pro.filing with exposu re to SP 25A.Treat ing L mono cytogenes
with SP 25A significantly altered the transcript profile of - 5% of the genes of the
genome. Addition of SP 25A repressed 97% of the 139 differentially regulated genes
(Table 4.3). The data set was also analyz ed for genes that were constitutively expressed
above the mean level during the treatment in an effort to find genes that may be essential
for survival of bacteri a under the antimicrobial stress . No genes were found that were
constitutively expressed above the mean . Most functional categori es contained genes that
were repressed . No categories contained genes that were only induced . However , a few
categories (ABC transporters , carbohydrate metabolism , transcription regulators,
secretion, virulence factors, and unknown genes) contained genes that were induced and
repressed.
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Cell division. Four genes involved in cell division and chromosome replication
were repressed. Genes required for cell division initiation protein , Div IV A (LMO 1888),
ATPase associated with chromosome architecture /replication (LM02759), DNA gyrase
subunit B (gyrB) , and DNA gyrase subunit A (gyrA) were repressed with addition of SP
25A. The transcription factor , lytR, which is correlated to the decrease in activity of
autolytic enzymes (11), was also repressed (Table 4.4).

Membrane prot eins. PEP/PTS transporters specific for ~-glucosides , fructose , and
trehalose ; cx-mannosidase (a sugar hydro lase) ; and 22 other genes in carbohydrate
metabolism were differentially expressed during the treatment time . From the entire set
of genes in the intermediary metabolism category , only L-glutamine-fructose-6phosphate transaminase (LM00726) and 6-phospho-~-glucosidase (LM00739) were
induced at T30.However , at T, 2o all of the 26 genes in sugar transport and intermediatery
metabolism were repre ssed (Table 4.4). Eac h PEP/PTS components were repressed after
120 min (Table 4.4).
In addition to the sugar transporters and A TPases that were repressed, the largeconductance mechonosensitive ion channel (LM02064) was induced at T 30, but repressed
at T120- This mechanoreceptor is involved in osmoregulation. Other studies using gene
expression profiling did not observe an expression change in this ion channel , despite its
importance in restoring the osmotic stability in a cell. This observation may be indicative
of membrane perturbation early in the treatment time.

Jntermediatery metabolism and respiration. The repressed genes in central
intermediatery metabolism included genes involved in glycolysis - 6-phospho-beta-
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glucosidase (LM00739) , the pyruvate dehydrogenase operon (pdhA, pdhB , pdhC , pdhD),
lactate dehydrogenase (ldh), pyruvate kinase (pykA), and phosphoglyceromutase
(LM02205). Repression of genes in the pentose phosphate pathway were also observed ribose 5-phosphate isomerase (LM00736) , transaldolase (LM02743) , ribul ose 5phosphate 3-epimerase (LM00735 , LM02659) , and fructose-1 ,6-bisphosphate aldolase

(jbaA). The dihydroxyacetone kinase enzyme complex (LM02695 , LM02696 and
LM02697) , which is responsible for phosphorylation of dihyroxyacetone and glycerol
prior to entry into the glycolytic pathway , was also repressed. Four (out of six) genes
involved in Fe-S cluster biosynthesis (sujD, lscU, sufB, cysteine desulfurase (LM02413))
were repressed.
Repression of key genes for cellular respiration was observed. After 120 min , two
genes (out of eight) of the H+ transporting ATP synthase enzyme complex , which code
for the alpha and c subunits (atpA and atpE) , were repressed. Three of the four subunits
for quinol oxidase (LM00014, LM00015 , LM00016) were also repressed.

Protein biosynthesis. At T30 two genes involved in protein biosynthe sis,
(LM025 l 1 and rpsU) were induced. The gene LM025 l l codes for the ribosome
associated factor Y, which is a global translation inhibitor , while rpsU codes for the S21
protein in the 30s ribosomal complex. After 120 min of treatment with SP 25A, three of
the four subunits of RNA polymerase (rpoA, rpoB, rpoC) were repressed . After 120 min
1 1 ribosomal proteins (out of 59) were repressed and two elongation factors (out of total
four) were repressed. Hence , after 120 min genes needed for transcription and tran slation
were repressed .
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Virulence factors. At T 30 two of the virulence genes hly (listeriolysin O precursor)
and fibronectin binding protein (LM00727) were induced , while iap (an invasion
associated protein) was repressed. At T 120, phospholipase C (plcA) was also repressed.
Hence , after 120 min SP 25A led to the repression of four genes directly required for host
invasion by L. monocytogenes.
Stress response. At T 30 five stress-related genes were repressed , while four genes
were induced. Among the repressed gene s two chaperone protein s (gro EL, grp E), tlu·ee
oxidative stress genes (sod , msrA , trxB) , and one gene related to toxic ion resistance
(LM01967). During the same period, the induced stress proteins were DNA binding
protein (fri) , organic hydroperoxide resistance protein (LM02 l 99), arsenate reductase
(LM02230) , and a universal stress protein (LMO 1580). After 120 min , an additional six
stress related genes were repressed. These included hrcA (a negative regulator of class I
heat shock genes) , a general stress protein (LMO 160 I) , a protein related to oxidative
stress (msrB) , and three genes involved in DNA recombination and repair (i.e . single
strand binding protein (ssb ), an endonuclease involved in recombination (LMO 1502), and
exinuclease ABC subunit A (urvA)). Three ATP-dependent endopeptidases needed for
protein turnover (clpE, clpB , clpX)(22) were also repressed . At T30one transcription
regulator of the marR family (LM02200) , which is a negative regulator of antibiotic
resistance proteins in E. coli (2) was induced, while at T 120another transcription of the
same family (LM00266) was repressed.

66

Discussion
This study explored the cellular response to treatment with two antibacter ial
compounds that presumably target the cell membrane for inhibition (5, 12, 2 1). The cell
permeabilization , cell density , and the transcription profile between these compounds
were markedly different. RLs caused an increase of - 53% in membrane
permeabilization , and inhibited growth by - 4 7%, a reasonable correlation between
membrane permeabilization and growt h inhibition. Converse ly, SP 25A permeabilized
the membran e by - 2% , but led to complete inhibiti on of cell growt h, demonstra ting the
disconnection between membrane permeabilization and cell growth inhibition . Other
studies with E. coli and S. aureus have made similar observations (16, 35). Friedrich et al.
(16) observed that treatment of S. aureus with CP26, an a-helical peptide , led to only
partial membran e depo larization, even with 90% inhibition of the population. Wu et al.
(35) found similar results using CP26 and bactenecin in E. coli. Tomas insig et al. (32)
found that a specific sequence of a praline-rich peptide interacted with the membrane
leading to growth inhibition and that the same peptide fragment led to gene expression
changes that were not related to membrane disruption. In contrast this study found RLs
to be linked to membrane disruption to bacterial inhibition for lytic activities .
Alternatively, use of SP 25A confirmed that additional mechanisms beyo nd membrane
disruption for bacterial inhibition may be involved.
With this observation , gene expression profiles were used to determine the genetic
targets of these bacterial inhibitors . SP 25A significantly changed expression of 139
genes , while RLs significantly changed expression of 39 genes. Both the compounds
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affected twenty-one common genes , but the expression profile for all these genes ( except
sujB) was significantly different. While SP 25A caused repression of all these genes after
120 min of treatment , RL s caused an induction (Table 4.3) , lendin g support to the
observation of growt h inhibition by SP 25A (Fig. 4 .1). Tomasinsig et al. (32) found that
genes from the same functional categories to be repressed with the Bac7 ( 1-35) peptide
fragment in E. coli.
SP 25A repressed key genes involved in cell division . After 120 min four prot eins
invo lved in cell divi sion were repres sed; two DNA gyrase subunits , one was an A TPase
assoc iated with chromosome rep licat ion , and one wa s the cell division initiation protein,
Div IV A, which is crucial for the initiation of cell division (15). Hence , repre ssion of this
protein alone would inhibit cell division (15). RLs , in contrast , did not affect any of the
proteins involved in cell division and had only a small reduction in cell density (Fig. 1).
In addition , repression of ly tR was correlated to a decrease in autolytic enzyme activit y,
which resulted in inhibition of cell divi sion in S. mutans (11 ). Use of SP 25A also led to
repression of fytR in L. monocytog enes in this study. These observation s ex plain the
inhibition of growth , rather than membrane disruption, with the addition of SP 25A. It
also points to the regulatory link between lytR and Div IV A to completely inhibit cell
growth (Fig. 4. lA , Table 4.4).
SP 25A caus ed significant changes in intermediary metabolism, especially
glycolysis and pathways needed for energy production (Table 4.4). Repression of central
metabolism would lead to a lack of enzymes needed for generation of precursor
metabolites and energy needed for growth. Repression of pyruvate dehydrogenase
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complex (8- to 16-fold), pyruvate kinase (1.6 fold), and phosphoglyceromutase

(1.5 fold)

would virtually stop energy production from glycolysis.
Glycolytic intermediates are also important for generation of acetyl CoA ,
pyruvate and phosphoglycerate, which are precursor metabolites for production fatty
acids and amino acids . RLs induced expression of the E3 subw1it of pyruvate
dehydrogenase , phosphoglyceromutase , and two more enzymes in the pentose phosphate
pathway , indicating that glycolysis was induced and energy production improved . This
may explain the reduction in membrane permeabilization after 120 min of exposure to
RLs. In contrast , addition of SP 25A , five enzymes in the pentose phosphate pathway
leading to generation of ribose-5-phosphate , which acts as a precursor metabolite in
purine and pyrimidine metaboli sm, were represse d by 1.5-to 3- fold. Th e lack of
induction of alternative pathways for formation of these metabolites left the cell with no
method to produce energy or intermediates to use in cell division. The same repression of
several key enzymes of the central intermediatery metabolism was also observed in E.

coli when challenged with sub-MIC doses of Bac7(1-JS), including sugar transporters and
glycolytic intermediates , which was associated with inhibition of cell growth (32).
SP 25A led to a - 5-fold repression of four proteins needed for synthesis of Fe-S
clusters . These are essential in diverse reactions , including electron transport , regulation
of gene expression, and mediation ofredox as well as non-redox catalysis (4). SP 25A
also caused down regulation of two subunits of the proton pump by 1.5-fold and quinol
oxidase by 2-fold, causing disruption of the oxidativ e phosphory lation machinery . RLs in
contrast led to a 3-fold induction of one subunit of proton pump (atp/<.,
J at T 30 and a 3.5-
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fold repression at T 120.Hence, after 120 min SP 25A repressed the cells ability to
generate precursor metabolites , as well as energy , while RLs did not have that effect at
all. In E. coli, repression of iron metabolism was found only in transport (jecA), other
genes were not affected (32).
Genes associated with transcription and translation were repressed between 1.5and 12-fold with the addition of SP 25A. It repressed three out of four RNA polymerase
subunits by 1.5- to 2-fold , which completely disrupted transcription. Coupled to this
decline , translation activity was also repressed. This effect was widespread with
repression (1.5- to 4-fold) of 11 ribosomal genes after 120 min, and two elongation
factors (2.5- to 12-fold). Contrary to this study, Tomasinsig et al. (32) observed an
induction of ribosomal genes after exposure to a pro line rich antibacterial peptide.
Regulation of stress-related genes was widespread with the addition of SP 25A
(Table 4.4). Multiple systems were regulated during the exposure time , which included
osmotic regulation , DNA repair , chaparonenes, and peroxide resistance. For example ,
the large conductance mechonosensitive channel (mscL) was induced at T 30, but was
repressed at T ,20. This gene is associated with hypo-osmotic shock (31) , likely caused by
the interaction of SP 25A with the membrane. Induction of mscL demonstrates the cells
effo1i to modulate the osmotic change with the addition of SP 25A. Repression of the
membrane protein at T120likely indicates that the cell is no long er under osmotic stress.
This exp lanation seems likely considering the membrane permeabilization declined at
T,20. No other group (17, 25, 32) has observed this phenomenon in response to an
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antimicrobial peptide, despite observing changes in membrane and transport proteins
associated with sugar and ion flux.
Interestingly , in all cases, stress-associated genes were repressed after 120 min of
exposure to SP 25A. This may indicate that the cell has adapted to the effects of SP 25A ,
but it may also represent the inability to produce new RNA and proteins with the
repression of the transcription and translation apparatus observed in this study. Three
Clp A TPase implicated in regulation of the stresses by virtue of their protein reactivation ,
remodeling activities , and their capacity to target misfolded proteins for degradation (22)
were repressed by SP 25A. There are no reports in literature of stress related genes bein g
repressed in response to exposure with antimicrobial peptides (1, 10, 17, 32, 34).
Four virulence genes essential for intracellular survival of L. monocytogenes were
repressed with treatment with SP 25A after 120 min of exposure. Fibronectin binding
protein and hly were induced and iap was repressed at T 3 o, but after 120 min each of these
genes and plcA were repressed. In contracts , addition of RLs induced hlyA expression
after 120 min . Down-regulation of these genes would make L. monocytogenes EGDe less
virulent with extended exposure by repressing the binding proteins and impairing the
capacity for intracellular survival as well (20).

Conclusion
Treatment of L monocytogenes EGDe with sub-MIC doses of SP 25A and RLs
led to complete inhibition of growth or a reduction of growth, respectively . However , this

71
inhibition was uncoupled from membrane perrneabilization in the case of SP 25A. The
gene expression profile of cells treated with SP 25A revealed that genes related to cell
division, chromosome replication, intermediatery metabolism , transcription, translation ,
and virulence were repressed. These effects were not produced in cells treated with RLs.
These observations indicate that SP 25A permeabilizes the membrane , but the
mechanisms associated with cell death are likely related to other targets that inhibit cell
division ; while, the antibacteria l activity of RLs is likely due to its interaction with the
membrane.
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Table 4.1. Functional categories that contained the genes that were significantly
differentially expressed in response to treatment with sub-MIC doses of RLs .
No. of differentially expressed genes
Functional category

A BC transporters
Ion channels
PEP/PTS components
Polysaccharide degradation
Central intermediate,)' metabolism
Cofactor and coenzyme metabo lism
Amino ac id metab olism
Electron tran sport and oxidative
phosphmylation
Cell wall metabolism
Transcription regulators
Transcription
Protein biosynthesis
Protein fate
Secretion
Virulence factors
Stress
Ce ll division
Phage protein s
Unknown /Hypoth etical proteins
Total

Total
genes 111
category
134
4
80
18
272
116
179

T30
Induced

Repressed

Induced

Repressed

0
0
0
0
0
0
0

0
0
0
0
I
0
0

2
0
3
I
4
0
2

0
0
0
0
0
0

0

0

0
0
0
0
I
0
0
0
0
0
0
2

0
2
0

61
57
142
36
158
92
63
131
50
17
18
1628

Tl20

0
I

0
0
0
0
0
0
I

4
8

I

0
0
0
I

I

2
0
0
7
27

0
0
0
0
0
2
2
7

77

Table 4.2. Significantly differentially regulated genes during exposure to RLs.
Log2 Ratios
ORF

Cellular Role

ABC transporter (Metal binding protein)

LM01073

ABC transporter (ATP-bind ing protein)
ABC transporter-associated protein, sufB

Protein

T30

T120

Q
value

A BC transporter s

-0. 18

0.97

0.26

LM02 l 93

A BC transporters

0.33

0.32

O. ll

LM024l I

ABC transporters

-0.43

-0.17

0.23

Fructose-specific phosphotransferase
enzyme IIB
Fructose-specific phosphotransferase
enzyme ITC
Beta-glucoside-specific enzyme TIABC
component

LM00399

PEP/PTS components

0.21

0.38

0.11

LM00400

PEP/PTS components

0.05

2.54

0.11

LM00738

PEP/PTS components

0.46

1.36

0.11

Alpha mannosidase

LM00401

-0. 15

2.70

0. 11

Ribose 5-phosphate isomerase

LM00736

-0.03

1.72

0.11

6-phospho-beta-glucos idase

LM00739

0.04

2.86

0.1 I

Pyruvate dehydrogensae ( dihydrolipoamide
dehydrogenase , E3 subunit) , pdhD

LMOI055

0.24

0.96

0.11

Phosphoglyceromutase

LM02205

-0.73

0.86

0.15

Ribulose-phosphate 3-epimerase

LM0 2659

0.0 I

1.70

0. I I

G Jyc ine dehydrogenase (decarboxylating)
subunit 2

LM01350

-0.4 I

1.21

0. I I

Threonine 3-dehydrogenase

LM02663

-0.06

1.98

O.l I

1.64

- I .81

0.11

H+-transporting ATP synthase C chain,
atpE

LM02534

Polysaccharide
degradation
[ntermediatery
metabolism
lntermediatery
metabo lism
Intermediatery
metabolism
Intermediatery
metabolism
lntermediatery
metabolism
Aminoacid
metaboloism
Aminoacid
metaboloism
Respiration and
oxidative
phsphorylation

Peroxide operon regulator, perR

LMOJ683

Transcription regulator

-0. 13

1.03

0.11

Transcriptional regulatory protein degU

LM02515

Transcription regulator

0.12

1.39

0.16

LMOl221

Protein biosynthesis

0.62

-0.45

0.29

LM00624

Post translational
modification

-0.62

I.OJ

0.29

LM00997

Protein degradation

-0.03

1.28

0. I I

LM00737

Secretion

0.05

1.02

0. I I

Phenylalanyl-tRNA synthetase alpha chain,
pheS

Acetyltransferase
ATP-depe ndent endopeptidase clp ATPbinding subunit, clpE
Oxidoreducatse involved in TA Tpathway
secrete d proteins
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Iisteriolysin O precursor , hfy

LM00202

Virulence

0 .24

1.90

0.11

Single-stranded DNA-binding protein, ssb

LM00045

Stress

-0.01

1.33

0.11

Cold shock protein, cspL

LMOl364

Stress

0.14

0.45

0.29

Non-heme iron-bindin g ferritin ,.fi'i

LM00943

Stress

0.09

0.81

0.11

Phage proteins

LM02287

Phage proteins

0.66

-0 .58

0.11

Phage proteins

LM02327

Phage proteins

0.27

-0 .6 1

0.11

Hypothetical Protein

LM00743

Unknown

0.12

0.82

0.15

Hypothetical Protein

LM01113

Unknown

0.77

-0.39

0.11

Hypothetical Protein

LM02257

Unknown

0.00

0.94

0.1!

Hypothetical Protein

LM02432

Unknown

-0.20

3.24

0. 11

Stage V sporulation protein G

LMOOl97

Others

0.86

-0. 61

0.11

Rhodanese-related

LM01384

Others

0.60

-0.48

0.11

Glycerol uptake facilitator protein

LMOl539

Others

0 .21

0.82

0.14

Creatinine amidohydrolase family protein

LM01968

Others

0.77

-0.56

0. 11

Protease I

LM02256

Others

0.17

0.99

0.26

LM02728

Others

-0.05

0.63

0.15

LM02334

Others

0.57

-0 .66

0.15

sulfurtransferases

Putative tran scr iptional regulator, McrR
family
Putative transcriptional regulator , MerR
family
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Table 4.3. Functional categories that contained the genes that were significantly
differentially expressed in response to treatment with sub-MIC doses of SP 25A.
Number of differentially expressed genes
Functional category

Total
genes m
category

T30
Induced

ABC transporters
Ton channels
PEP/PTS components
Polysaccharide degradation
Central intermediatery metabolism
Cofactor and coenzyme metabolism
Amino acid metabo lism
Electron transport and oxidative
phosphorylation
Cell wall metab olism
Transcription regulator s
Transcription
Protein biosynthesis
Protein fate
Secretion
Virulence factors
Stress
Cell division
Phage proteins
Unknown /Hypothetical proteins
Total

T120

Repressed

Induced

Repressed

3
0
4

2
0
0
0
0
0
0

8
4
I
24
5
4

134
4
80
18
272
116
179

0
0
2
0
0

61

0

4

0

5

57
142
36
158
92
63
13 I
50
17
18

0
I
0
2
0

I

0

0
0
3
,,

I

2
4
3
12
4
3
4
13
4
0
34
135

1628

I

2
4
0
0
12
26

13
4

.)

2
I
5
2
0
13
60

0
0
0
0
0
0
0
0
2
5

80
Table 4.4. Significantly differentially regulated genes during exposure to SP 25A.
Log 2 Ratios
Protein

ORF

Cellu lar Role

Manganese uptake Mn ABC transporter

LM01847

Metal cations ABC transporter , permease
protein

T30

T120

Q
value

A BC transporters

0.66

-3.85

0 .00

LMOl848

A BC transporters

-3.43

-2.43

0.00

ABC transporter, ATP-binding protein

LM02415

A BC transporters

-0.47

-0.65

0.00

Heavy metal-transporting A TPase

LM00641

A BC transporters

-0.45

-0.42

0.01

Manganese transport proteins NRA MP

LM01424

A BC transporters

-2.10

0.01

0.01

LM01849

A BC transporte rs

-0.89

-0 .78

0.04

LM0241 I

A BC transporters

-0 .51

-0.20

0.04

LM02193

ABC transporters

-0.24

-0.46

0.17

Acetoin uptake permease protein

LM02239

ABC transport ers

-0.24

0.68

0.17

ABC transporter (ATP-binding protein)

LM02 139

ABC transporters

0.07

0.60

0.23

LM02064

Ton Channel

1.96

-2.70

0.00

LM00400

PEP/PTS components

-1.78

-0 .34

0.00

LM02373

PEP/ PTS compone nts

0.39

-0.83

0.00

LM00738

PEP/PTS components

-1.04

-1.04

0.00

Trehalose specific enzyme lIBC

LMOl255

PEP/PTS components

-3.74

-0.40

0.00

Alpha mannosidase

LM00401

Polysaccharide
degradation

-2 .6 1

-0.78

0.00

6-phospho-beta-glucosidase

LM00739

0.97

-2.39

0.00

6-phospho-beta-glucosidase

LM00536

-038

-0.24

0.23

A lpha ,alpha-ph osphotrehalase

LMOl254

-2.10

-0.04

0.00

-2.74

-0.38

0.00

-3 .04

- l.38

0.00

-2 .04

-2.62

0.00

Metal cations ABC transporter, ATPbinding proteins
A BC transporter-associated protein
(suffi)
Oligopeptide ABC transporter (ATPbinding protein)

Large conductance mechanosensitive
channe l
Fructose-specific phosphotran sferase
enzyme rrc
Beta-glucoside-specific enzyme llA BC
component
Beta-glucoside-specific enzyme !IA BC
component

Pyruvate dehydro genase (EI alpha
subunit), pdhA
Pyruvate dehydrogenase (EI beta
subunit), pdhB
Pyruvate dehydrogenase
(dihydrolipoamide acetyltransferase E2

LMOI052
LMOI053
LM01054

I ntermediatery
metabolism
lntermediate1y
metabolism
lntermediate,y
metabolism
Tntermediate1y
metabolism
Intermediatery
metabolism
Intermediatery
metabolism
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subunit), pdhC
Pyruvate dehydrogensae (
dihydrolipoamide dehydrogenase,
subunit), pdhD

LM01055

lntermediatery
metabolism

-2.58

-2.31

0.00

L-lactate dehydrogenase , ldh

LMOI057

fntermediatery
metabolism

- I. 11

-0.52

0.04

Pyruvate kinases, pyk.A

LMOl570

-0.60

0.38

0.03

Ribose 5-phosphate isomerase

LM00736

lntermediatery
metabolism

-0.81

-0.32

0.00

Ribulose-5-Phosphate

LM00735

Intermediatery
metabolism

-0.43

-0.48

0 00

-0.62

-0.13

0.29

-0.22

-0.38

0.07

-0.49

-0.71

0.03

-0.51

-0.81

0 .00

0.41

-1.51

0.01

-0.52

-0.31

0.07

0.76

-2.90

0.00

E3

3-Epimerase

Transaldolase

LM02743

Fructose-1,6-bisphosphate

aldolase ,.fbaA

LM02556

rntermediatery
metabolism

lntermediatery
metabolism
rntermediatery
metabolism
Intermediatery
metabolism
Intermediatery
metabolism
Intermediatery
metabolism
lntermediatery
metabolism
lntermediater y
metabolism

Dihydroxyacetone

kinase

LM02695

Dihydroxyacetone

kina se

LM02696

Dihydroxyacetone kinase
phosphotransfer protein

LM02697

Glucosam ine-6-Ph oasp hat e isomerase

LM00957

L-gl utam ine-0- fructose-6-phosphate
amidotransferase

LM00727

Phosphoglyceromutase

LM02205

fntermediatery
metabolism

-0.21

-0.42

0.03

Branched-chain alpha-keto acid
dehydrogenase E2 subunit (lipoamide
acy ltran sferase)

LMOl374

Amino acid metabolism

-0.56

-0.11

0.03

G lycerate dehydrogenases

LMOI684

Amino acid metabolism

-1.26

-1.22

0.00

Glyc ine dehydrogenase (deca rboxylating )
subunit 2

LM01350

Amino acid metabolism

-0 .34

-1.68

0.00

A Ian ine dehydrogenase

LMOl579

Amino acid metabolism

-0.38

-0.25

0.00

IscU protein

LM02412

Cofactor-coenzyme
metabolism

-1 .39

-1.00

0.00

Cysteine desulfurase

LM024 13

Cofactor-coe nzym e
metabolism

-2.04

-0.40

0.10

SufD protein

LM02414

Cofactor-coenzyme
metabolism

-1 .50

-0.94

0.00

Pyridoxine biosynthesis protein

LM02101

-1.82

-0.40

0.00

Pyridoxine biosynthesis amidotransferase

LM02102

-0 . 15

-0.83

0.00

AA3-600 quinol oxidase subunit I

LMOOOl4

-0 .91

-0 09

0. I 0

Cofactor -coenzyme
metabolism
Cofa ctor-coenzyme
metabolism
Respiration and
oxidative phsphorylation
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AA3-600 quinol oxidase subunit JJJ

LMOOO l 5

Respiration and
oxidative phsphorylation

-0 .73

-0.50

0.03

AA3-600 quinol oxidase subunit IV

LMOOOl6

Respiration and
oxidative phsphorylation

-0.52

-0.37

0.17

LM02531

Respiration and
oxidative phsphorylation

-0.58

0 . 11

0 .29

LM02534

Respiration and
oxidative phsphorylation

-1.14

0 .32

0.00

LM02526

Cell wall metabolism

- I. l 0

-0 .21

0.00

LM02714

Cell wall metabolism

-0 .03

-0.98

0 .00

H+-transporting ATP synthase chain
alpha, atpA
H+-transporting ATP synthase C chain ,
atpE
UDP-N-acetylglucosamine
1carboxyvinyltransferase , murA
Peptidoglycan anchored protein (LPXTG
motif)
Transcriptional

regulator , MarR family

LM00266

Transcription regulator

-0.25

0 .89

0.29

Transcriptional

regulator , MarR family

LM02200

Transcription regulator

0.62

-2 .07

0 .00

Transcriptional

regulator , Ly tR family

LM00433

Transcription regulator

-0.5 3

-0.80

0.01

Heat-inducible transcription repressor ,
hr cA

LMOl475

Tran scription regulator

-0 .56

-0.16

0.00

Peroxide operon regulator , p erR

LMOl683

Tran scription regulator

0.28

-2.71

0 .00

Negative regulator of genetic competence
me cA

LM02190

Transcription regulator

0.24

-0.62

0.02

RNA polymerase (alpha subunit),1p oA

LM02606

Transcription

-0.3 I

-0 .30

0.01

RNA polymerase (beta subunit),rpoB

LM00258

Transcription

-0.47

-0.76

0.02

RNA polymerase (beta' subunit) , rpoC

LM00259

Transcription

-0.12

-0.46

0 .00

Ribosomal protein S6 , 1psF

LM00044

Protein biosynthesi s

-0.47

-0.70

0.00

Ribosomal protein S 18, rpsR

LM00046

Protein biosynthe sis

0. 15

-0.67

0.00

Ribosomal protein S2 l , rpsU

LMOl468

Protein biosynthesis

1.37

-2 .22

0.00

Ribosomal protein L 16, rp!P

LM02625

Protein biosynthesis

-0 .16

-0.56

0.00

Ribosomal protein L2, rp!B

LM02629

Protein biosynthesis

-0 .52

-0.29

0.00

Ribosomal protein S2, rpsB

LMOI658

Protein biosynthesis

-0.26

-1.04

0.02

Ribosomal protein L27 , rpmA
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Fig 4.1. Membran e permeabili zation determined by the increase in fluorescence (RFU)
with PI uptake during treatment of L. monocyto genes with SP 25A and RLs (A), and cell
growth when treated with SP 25A, RLs and saline (control) over a period of 120 min (B).
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CHAPTER 5
SUMMARY

Development of antibiotic resistance in bacteria is one of the most troublesome
issues facing health sciences today. There is no certain way to circumvent this problem ,
but discovery and development of novel compounds that inhibit bacteria by different
mechanisms is required on a consistent basis. Secondary metabolites from
microorganisms have been the most abundant source of new antimicrobials in the past.
This study used two secondar y metabolites from fluorescent pseudomonads ,
syringopeptin 25A (SP 25A) and rhamnolipids (RLs) , a lipodepsipeptide and a surfactant,
respectively , to determine the potential for their use as antimicrobial agents.
Several criteria must be met before a compound can be added to the arsenal of
antibiotics in daily use: 1) the range of activity against bacteria must be known , 2) the
MIC must be low enough to permit active doses that are not toxic , 3) an estimation of the
mechanism of action must be determined , 4) the pharmacokinetics of the compound fate
must be known, and 5) the compound must be approved for human use. This study
focused on the first three criteria as a measure of the need to pursue criteria four and five.
Both the compounds, though from different chemical classes , are thought to act
on the bacterial cell membrane to cause cell lysis and death . RLs have a very low critical
micelle concentration (1-1 Oµg/ml) and are thought to have a detergent-like action on the
bacterial cell membrane causing it to dissolve (2). SP 25A, and syringopeptins generally ,
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on the other hand is thought to form transmembrane pores in the cell membrane; thereby ,
disrupting the permeability barrier of the bacteria ultimately leading to lysis (4, 7).
Previous studies with these compounds showed that they inhibit a number of bacteria , but
the range of organisms used was somewhat limited (1, 2, 5, 6). However , an everincreasing data set is emerging that is challenging these models for antimicrobial action.
These studies screened a large number of diverse bacteria and mold to determine the
activity range of these two compounds , subsequently, used gene expression arrays during
exposure of Listeria monocytogenes to sub-M IC dos es of these compounds to determine
non-membrane targets associated with growth inhibition.

Hypothesis
Syringopeptin 25A (SP 25A) and rhamnolipids (RLs) inhibit many bacterial
species by disrupting the cellular membrane .

Objectives
1. Screen candidate compounds for microbial inhibition and determine the minimum
inhibitory concentration for these compounds against selected bacteria
2. Determine the cellular responses to sub-MIC levels of SP 25A and RLs using
gene express10n arrays.
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To screen the antimicrobial potential of these compounds they were tested against 27
different organisms , which included Gram-positive and Gram-negative bacteria and mold
that are multiple drug resistant human pathogens, food spoilage organisms, bacterial
spores, and fermentative bacteria . The initial screening was done using a rapid technique
to determine the membrane permeabilization with a fluorescent DNA-binding dye that is
blocked from entering the cell by an intact membrane. Subsequently, the MIC for each
compound with each inhibited organism. Both the compounds inhibited growth of all the
Gram -positive organisms . Mycobacterium smegmatis, the surrogate test organisms for

Mycobacterium tuberculosis, was also inhibited. SP 25A also inhibited the. Interestingly ,
SP 25A inhibited two multiple antibiotic resistant strains of Staphylococcus aureus and

Enterococcus faecalis and spore germination of bacterial spores. For all the organisms
tested SP 25A showed similarly lower MIC values as compared to RLs with a range from
3 µg/ml to 16 µg/ml; reasonable concentrations for therapeutic use .
While the MICs were reasonable , we sought to reduce it further by combining the
compounds to determine if they were synergistic in their activity. We demonstrated a
synergistic activity against Listeria monocytogenes , which allowed the concentration of
SP 25A to be reduced to below the MIC level , yet increase the cellular inhibition Neither
compound was toxic to three mammalian cell lines at the concentration of the effective
MICs. Hence , taking into account the lower MICs, anti-spore activity, antimycobacterial
activity, inhibition of multiple antibiotic resistant strains and no toxicity to mammalian
cell lines SP 25A appears to be a promising therapeutic agent.
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During the course of this study we observed a lack of correlation between
membrane permeabilization and growth inhibition for SP 25A. When L. monocytogenes
was challenged with sub-MIC doses of both the compounds, RLs induced PI uptake
while SP 25A did not , yet it completely inhibited cell growth. A number of other groups
have also observed that membrane-active antimicrobial peptides exert effects on cell
growth beyond their ability to interact with the membrane (3, 8). This apparent lack of
correlation between membrane permeabilization and inhibition of cell growth led us to
suspect that the pore forming model alone may not be responsible for all of the
antimicrobial properties of SP 25A. Therefore, we hypothesized that SP 25A represses
gene expression to cause growth inhibition . To test this we challenged L. monocytogenes
with sub-MIC concentrations of SP 25A and RLs and monitored gene expression profiles
before treatment with antimicrobials , 30 min after treatment , and 120 min after treatment
using a custom commercial high-density, whole genome oligonucleotide arrays (Chapter
4) .
The gene expression profile was distinct between the two antimicrobials. SP 25A
repressed genes required for cell division , chromosome replication and segregation,
intermediary metabolism , transcription , translation , and virulence genes. Conversely, RLs
induced a broad set of genes that were related to energy production. Hence , these data
indicate that even though both the antimicrobials may interact with a conunon cellular
structure (i.e. the cell membrane) their mode of action is different, with SP 25A having
little ability to damage the membrane, but substantial ability to inhibit production of
proteins critical to cellular replication . This supports the concept that antimicrobial
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peptides do not entirely rely upon their membrane permeabilizing ability to exert their
anti bacterial action . This study brings forth SP 25A as a promising therapeutic agent that
has a unique cellular target (e.g. Div IVA) to inhibit cell growth of a pathogenic bacterium
at a reasonable MIC.
Future work with this compound needs to demonstrate the other criteria for
antibiotics. Additional work needs to be done to assess the antimycobacterial potential
and the efficacy in vivo for the inhibition of other Gram-positive pathogens.
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APPENDIX A
COMPOUND PURITY
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Fig A 1. Massspectrogram of SP 25A purified from Pseudomonas syringae pv syringae Ml cultures .
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Fig A2.
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C NMR spectra of RL mixtur e obtained from Jeniel Biotech.
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APPENDIXB
VALIDA TI ON OF PI ASSAY

98

500
400
:::::,
LL

300

a:::

200
100----..-15
0

.....~....---.--.......- .... -...30 45 60 75 90 105 120
Time (Min.)

Fig B 1. Mean PI uptake by L. lactis IL1403 treated with saline (negative control for the
PI assay) over a period of 120 min.
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APPENDIXC
R CODE F'OR DAT A NORMALIZATION
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Code For RMA Normalization In R Of Raw
Data Received From NimbleGen Systems:
Library (affy)
Data=read. table(" lmono .txt" ,nrows=400000,sep="\t" ,check.names=false,header=true)
Corrected.data<-apply( as.matrix( data[,3: 14]),2,bg.adjust)
Normalized. data <-normalize .quantiles( corrected. data)
Probe.data <-cbind( data[ , 1:2],normalized.data)
Expression.data<-data.frame()
Seq.ids <-unique(a s.vector(probe.data$seq_id))
Express ion .data <-data.frame()
For (seq.id in seq.ids) { probes <new("probeset" ,id=seq .id,pm =as.matrix(subset(probe.data[ ,3: 14],probe.data$seq_id ==se
q.id)))
Ev= express.summary .stat(probes ,summary="medianpolish" ,pmcorrect="pmonly ")
Expression.data<-rbind( expression.data ,t( ev$exprs ))

}
Expression.data<-as .data. frame( cbind( seq .ids,expression.data))
Names( expression.data) <-names( data)[ c( 1,3: 15)]
write. table( expression.data,file=" nfile .txt" ,col.names=na ,quote=f ,sep=" \t")
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APPENDIXD.
HEATMAPS OF EXPRESSION DAT A
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Fig D4. Heatmap of all genes in L. monocytogenes involved in assembly of ribo somal complex when treated with subMIC doses of SP 25A and RLs over a period of 120 min. (Figure of ribo somes adapted from KEGG
(www.genom e.jp/kegg/kegg2 .html)). Genes significantly down regulated (Q<0 .3 and atleast a 1.5 fold change) by SP
25A denoted by~ I-'
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